J&J says its lung cancer drug combination keeps people alive longer

CNBC January 7, 2025
Angelica Peebles

Key Points

– Johnson & Johnson said a combination of its lung cancer drugs Rybrevant and Lazcluze kept people alive for at least a year longer than AstraZeneca’s Tagrisso in a clinical trial.

– J&J is trying to supplant AstraZeneca’s blockbuster Tagrisso, a once-daily pill that has transformed the treatment of non-small cell lung cancer with EGFR mutations.

– It remains to be seen how many doctors will adopt the treatment.

Johnson & Johnson on Tuesday said its lung cancer regimen keeps people alive for at least a year longer than AstraZeneca‘s Tagrisso, the go-to drug for a certain type of lung cancer.

J&J in a statement said its drugs – Rybrevant and Lazcluze – showed a statistically significant and...

Today's Sponsors

Today's Sponsor